Drug
Fludarabine clinical trials
Also written Fluradosa.
Includes 250 studies of Fludarabine phosphate.
How each study uses fludarabine is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the fludarabine studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- 18 Apr 1991 · FLUDARA · NDA 020038 (FDA, Drugs@FDA; as fludarabine phosphate)
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
734 studies that test it; most in 2005 (38); 7 more planned to start later
| Year | Studies |
|---|---|
| 1994 | 1 |
| 1995 | 3 |
| 1996 | 2 |
| 1997 | 4 |
| 1998 | 14 |
| 1999 | 16 |
| 2000 | 18 |
| 2001 | 23 |
| 2002 | 29 |
| 2003 | 30 |
| 2004 | 30 |
| 2005 | 38 |
| 2006 | 30 |
| 2007 | 31 |
| 2008 | 25 |
| 2009 | 23 |
| 2010 | 27 |
| 2011 | 22 |
| 2012 | 22 |
| 2013 | 18 |
| 2014 | 23 |
| 2015 | 19 |
| 2016 | 24 |
| 2017 | 35 |
| 2018 | 29 |
| 2019 | 17 |
| 2020 | 27 |
| 2021 | 23 |
| 2022 | 17 |
| 2023 | 29 |
| 2024 | 18 |
| 2025 | 31 |
| 2026 | 36 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 59 · Other 685
Fred Hutchinson Cancer Center (68) · M.D. Anderson Cancer Center (67) · National Cancer Institute (NCI) (42) · Masonic Cancer Center, University of Minnesota (28) · City of Hope Medical Center (20) · Memorial Sloan Kettering Cancer Center (20) · St. Jude Children's Research Hospital (16) · Baylor College of Medicine (15)
Often tested with
Tested in the same studies.
Cyclophosphamide (393) · Busulfan (149) · Melphalan (109) · Mycophenolic Acid (94) · Rituximab (88) · Tacrolimus (74) · Antilymphocyte Serum (54) · Thiotepa (51)
Related medicines
As reviewed, each with the page that says it.
- One of Antimetabolites source
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Tested against it · 3 phase 3 studies under way
Fludarabine is the comparator. A study of two new drugs counts under both.
- 1Ibrutinib · National Cancer Institute (NCI)
- 1ARQ531 · Merck Sharp & Dohme LLC · next primary completion May 2027
- 1Lisaftoclax · Ascentage Pharma Group Inc. · next primary completion Aug 2027
- 1Acalabrutinib · Ascentage Pharma Group Inc. · next primary completion Aug 2027
Reaching primary completion within a year · 53
Studies that test fludarabine.
- Nov 2026Study of Intensity Modulated Total Marrow Irradiation (IM-TMI) in Addition to Fludarabine/Busulfan Conditioning for Allogeneic Transplantation in High Risk AML and Myelodysplastic SyndromesPhase 2 · University of Illinois at Chicago
- Nov 2026Early Human Leukocyte Antigen (HLA) Matched Sibling Hematopoietic Stem Cell TransplantationPhase 2 · Emory University
- Nov 2026Reduced Intensity Conditioning for Non-Malignant Disorders Undergoing UCBT, BMT or PBSCTPhase 2 · Paul Szabolcs
- Nov 2026Metabolically Fit CD19 CAR T-cell Therapy With CD34 Selection in Patients With CD19+ Relapsed/Refractory NHL, CLL/SLLPhase 1/2 · Medical University of South Carolina
- Dec 2026Radiation- and Alkylator-free Bone Marrow Transplantation Regimen for Patients With Dyskeratosis CongenitaPhase 2 · Boston Children's Hospital
- Dec 2026BMT-06: Study of Intensity Modulated Total Marrow Irradiation (IM-TMI)Phase 2 · University of Illinois at Chicago
- Dec 2026HSCT for Patients With Fanconi Anemia Using Risk-Adjusted ChemotherapyPhase 2 · Children's Hospital Medical Center, Cincinnati
- Dec 2026Cord Blood Transplant in Children and Young Adults With Blood Cancers and Non-malignant DisordersPhase 2 · Memorial Sloan Kettering Cancer Center
- Dec 2026Allogeneic CD7 CAR γδ T Cells Therapy Recurrent/Refractory LeukemiaPhase 1 · Anhui Provincial Hospital
- Dec 2026GPC3 Targeted CAR-T Cell Therapy in Advanced GPC3 Expressing Solid Tumor MalignanciesPhase 1 · National Cancer Institute (NCI)
Studies
Open first, then newest update. How each study uses fludarabine is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 744
- Stem Cell Transplantation for Participants With Germline RUNX1 Associated Blood CancersNot yet recruitingPhase 2National Cancer Institute (NCI)NCT07524530Written as Fludarabine
- Genetically Engineered Cells (BAFFR-CAR T Cells) for the Treatment of Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia and B-cell Lymphoblastic LymphomaRecruitingPhase 1City of Hope Medical CenterNCT07758673Written as Fludarabine
- Dual-Targeting CAR-NK Cell Therapy for Recurrent/Progressive Glioblastoma and High-Grade GliomaRecruitingPhase 1Beijing BiotechNCT07480941Written as Fludarabine
- Dual-Target Nectin-4/HER2 CAR-NK Cells in Advanced Urothelial CarcinomaRecruitingPhase 1Beijing BiotechNCT07492628Written as Fludarabine
- Dual-target CLDN18.2/HER2 CAR-NK Cells for Advanced Gastric/GEJ CancerRecruitingPhase 1/2Beijing BiotechNCT07551362Written as Fludarabine
- Dual-Targeting CAR-NK Cells for Recurrent/Progressive Glioblastoma and High-Grade GliomaRecruitingPhase 1Beijing BiotechNCT07551336Written as Fludarabine
- A Study of Fludarabine Dosing in Children and Young Adults With B-cell Acute Lymphoblastic LeukemiaRecruitingPhase 3Memorial Sloan Kettering Cancer CenterNCT07223021Written as Fludarabine
- Lifileucel (TIL) Therapy After PD-1 Blockade Failure in Kidney CancerNot yet recruitingPhase 2Beth Israel Deaconess Medical CenterNCT07925333Written as Fludarabine
- Thiotepa + TBI + Fludarabine + Etoposide for Allo-HSCT in Patients With R/R or High-risk Acute LeukemiaEnrolling by invitationPhase 2Guangdong Second Provincial General HospitalNCT07920796Written as Fludarabine
- Evaluating Efficacy of B7-H3-CAR T Cells Administered at the End of Upfront Map Chemotherapy in Patients With Newly Diagnosed High-Risk OsteosarcomaRecruitingPhase 2St. Jude Children's Research HospitalNCT07428993Written as Fludarabine
- A Study to Evaluate Efficacy and Safety of Ciltacabtagene AutoleucelRecruitingPhase 2Janssen Research & Development, LLCNCT07149857Written as Fludarabine
- Phase 1/2 FLAG-IDA, VEN and Asciminib in CML and Ph+ AMLNot yet recruitingPhase 1/2M.D. Anderson Cancer CenterNCT07604233Written as Fludarabine
- Autologous T Cells Transduced With Retroviral Vectors Expressing TCRs for Participant-specific Neoantigens in Patients With Hematologic MalignanciesRecruitingPhase 1National Cancer Institute (NCI)NCT06904066Written as fludarabine phosphate
- MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)RecruitingPhase 2National Cancer Institute (NCI)NCT05564390Written as Fludarabine
- A Study to Investigate the Safety and Preliminary Efficacy of ALLO-329, an Allogeneic CAR T-cell Therapy, in Adults With Autoimmune DiseaseRecruitingPhase 1Allogene TherapeuticsNCT07085104Written as Fludarabine
- Consolidation of First-Line MRD+ Remission With Cema-cel in Patients With LBCLRecruitingPhase 2Allogene TherapeuticsNCT06500273Written as Fludarabine
- 225Ac-DOTA-Anti-CD38 Daratumumab Monoclonal Antibody With Fludarabine, Melphalan and Total Marrow and Lymphoid Irradiation as Conditioning Treatment for Donor Stem Cell Transplant in Patients With High-Risk Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia and Myelodysplastic SyndromeRecruitingPhase 1City of Hope Medical CenterNCT06287944Written as Fludarabine
- Administering Peripheral Blood Lymphocytes Transduced With a CD70-Binding Chimeric Antigen Receptor to People With CD70 Expressing CancersRecruitingPhase 1/2National Cancer Institute (NCI)NCT02830724Written as Fludarabine
- Genetically Engineered Cells (CD83 CAR T Cells) for the Treatment of Relapsed or Refractory Acute Myeloid LeukemiaRecruitingPhase 1Roswell Park Cancer InstituteNCT06871410Written as Fludarabine Phosphate
- Phase I/II Study of Engineered T Cell Receptor-Modified NK Cells Targeting PRAME in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapse/Refractory Myeloid MalignanciesRecruitingPhase 1/2M.D. Anderson Cancer CenterNCT06383572Written as Fludarabine phosphate
See all 744 studies that test fludarabine →
Given beside what is tested · 764 — fludarabine is usual care or a partner of the new treatment
- Metabolically Fit CD19 CAR T Cells With CD34 Selection Markers in Adults With CD19-Positive B-Cell Acute Lymphocytic LeukemiaNot yet recruitingPhase 1Medical University of South CarolinaNCT07896213Written as Fludarabine
- Anti-CRLF2-R/TSLPR Chimeric Antigen Receptor T Cells (TSLPR-CART) in Participants With Recurrent or Refractory CRLF2-R/TSLPR-Overexpressing B-Cell Acute Lymphoblastic Leukemia (B-ALL)RecruitingPhase 1National Cancer Institute (NCI)NCT07572136Written as Fludarabine
- IL-18 Armored STEAP1 CAR T Cells for the Treatment of Metastatic Castration Resistant Prostate CancerNot yet recruitingPhase 1Fred Hutchinson Cancer CenterNCT07803653Written as Fludarabine
- Disulfiram for Preventing Treatment Complications in Patients Undergoing CAR T-cell Therapy for Relapsed or Refractory Diffuse Large B-cell LymphomaNot yet recruitingPhase 1/2University of Michigan Rogel Cancer CenterNCT07932730Written as Fludarabine
- Allogeneic Hematopoietic Stem Cell Transplant for Patients With Inborn Errors of ImmunityRecruitingPhase 2National Cancer Institute (NCI)NCT04339777Written as Fludarabine
- Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic CancerRecruitingPhase 2National Cancer Institute (NCI)NCT01174121Written as Fludarabine
- Dual-Target GD2/B7-H3 CAR-NK Cells for Pediatric Relapsed or Refractory NeuroblastomaRecruitingPhase 1/2Beijing BiotechNCT07502287Written as Fludarabine
- Dual-Target CLDN18.2/HER2 CAR-NK Cells for Advanced Esophageal AdenocarcinomaRecruitingPhase 1/2Beijing BiotechNCT07622940Written as Fludarabine
- Arsenic Trioxide to Prevent Relapse in Patients Undergoing Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia or Myelodysplastic SyndromeRecruitingPhase 1University of Michigan Rogel Cancer CenterNCT07737769Written as Fludarabine
- GCAR1, a Chimeric Antigen Receptor (CAR) T-CELL Therapy for Relapsed/Refractory GPNMB-Expressing Solid TumoursRecruitingPhase 1Canadian Cancer Trials GroupNCT07297667Written as Fludarabine
- IL-12 Genetically Engineered Myeloid Cells in Participants With Relapsed, Refractory Solid TumorsRecruitingPhase 1National Cancer Institute (NCI)NCT07672483Written as Fludarabine
- The Lowest Effective Dose of Post-Transplantation Cyclophosphamide in Combination With Sirolimus and Mycophenolate Mofetil as Graft-Versus-Host Disease Prophylaxis After Reduced Intensity Conditioning and Peripheral Blood Stem Cell TransplantationRecruitingPhase 1/2National Cancer Institute (NCI)NCT05436418Written as Fludarabine
- CAR20(NAP)-T Therapy for B Cell Lymphoma (CARMA-01 Study)RecruitingPhase 1/2Uppsala UniversityNCT06002659Written as Fludarabine
- Donor Lymphocyte Infusion After Allogeneic Hematopoietic Cell Transplantation for High-Risk Hematologic MalignanciesRecruitingPhase 1/2National Cancer Institute (NCI)NCT05327023Written as Fludarabine
- Phase I/II Study to Reduce Post-transplantation Cyclophosphamide Dosing for Older or Unfit Patients Undergoing Bone Marrow Transplantation for Hematologic MalignanciesRecruitingPhase 1/2National Cancer Institute (NCI)NCT04959175Written as Fludarabine
- Emapalumab With Post-Transplant Cyclophosphamide, Tacrolimus and Mycophenolate Mofetil for the Prevention of Graft-versus-Host Disease After Donor Reduced-Intensity Hematopoietic Cell TransplantRecruitingPhase 1City of Hope Medical CenterNCT06996119Written as Fludarabine
- Autologous CAR-T Cells Targeting CSPG4 in Relapsed/Refractory HNSCCRecruitingPhase 1UNC Lineberger Comprehensive Cancer CenterNCT06096038Written as Fludarabine
- Anti-Mesothelin TNaive/SCM hYP218 (TNhYP218) CAR T Cells in Participants With Mesothelin-Expressing Solid Tumors Including MesotheliomaRecruitingPhase 1National Cancer Institute (NCI)NCT06885697Written as fludarabine
- A Study of the Efficacy and Safety of Lisocabtagene Maraleucel (Liso-cel) as First-Line Therapy in Adults With Transplant-Ineligible Primary Central Nervous System LymphomaRecruitingPhase 2Juno Therapeutics, Inc., a Bristol-Myers Squibb CompanyNCT07015242Written as Fludarabine
- Phase I/II Study of AD-PluReceptor Plus Tafasitamab-cxix and Lymphodepleting Chemotherapy in Patients With Autoimmune DisordersRecruitingPhase 1/2M.D. Anderson Cancer CenterNCT06434363Written as Fludarabine phosphate
Showing 20 of 764.
As the comparator · 24 — what is tested is compared with fludarabine
- Bendamustine Versus Fludarabine/Cyclophosphamide for Lymphodepletion in Chimeric Antigen Receptor T-cell Immunotherapy (CAR-T): a Randomized Trial.RecruitingPhase 2Swiss Cancer InstituteNCT07593482Written as Fludarabine
- A Study of Lisaftoclax (APG-2575) Combined With Acalabrutinib Versus Immunochemotherapy for Newly Diagnosed CLL/SLL.RecruitingPhase 3Ascentage Pharma Group Inc.NCT06319456Written as Fludarabine
- Study Comparing the Efficacy of 2 RIC Regimens (Clofarabine vs Fludarabine) in Adults With AML Eligible to Allo-SCTRecruitingPhase 2Nantes University HospitalNCT05917405Written as Fludarabine
- A Study of ASP2215 Versus Salvage Chemotherapy In Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase 3 (FLT3) MutationCompletedPhase 3Astellas Pharma IncNCT03182244Written as Fludarabine
- Haplocompatible Transplant Using TCRα/β Depletion Followed by CD45RA-Depleted Donor Lymphocyte Infusions for Severe Combined Immunodeficiency (SCID)Active, not recruitingPhase 1/2St. Jude Children's Research HospitalNCT03597594Written as Fludarabine
- Ibrutinib and Rituximab Compared With Fludarabine Phosphate, Cyclophosphamide, and Rituximab in Treating Patients With Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic LymphomaActive, not recruitingPhase 3National Cancer Institute (NCI)NCT02048813Written as Fludarabine Phosphate
- A Comparison of Reduced Dose Total Body Irradiation (TBI) and Cyclophosphamide With Fludarabine and Melphalan Reduced Intensity Conditioning in Adults With Acute Lymphoblastic Leukaemia (ALL) in Complete Remission. (ALL-RIC)Active, not recruitingPhase 2University of BirminghamNCT03821610Written as Fludarabine
- A Study of Nemtabrutinib vs Chemoimmunotherapy for Participants With Previously Untreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) Without TP53 Aberrations (MK-1026-008, BELLWAVE-008)Active, not recruitingPhase 3Merck Sharp & Dohme LLCNCT05624554Written as Fludarabine
- A Study to Compare the Efficacy and Safety of a Combined Regimen of Venetoclax and Obinutuzumab Versus Fludarabine, Cyclophosphamide, and Rituximab (FCR)/ Bendamustine And Rituximab (BR) in FIT Patients With Previously Untreated Chronic Lymphocytic Leukemia (CLL) Without DEL (17P) or TP53 MutationCompletedPhase 3Hoffmann-La RocheNCT04285567Written as Fludarabine
- Trial of DFP-10917 vs Non-Intensive or Intensive Reinduction for AML Patients in 2nd/3rd/4th SalvageTerminatedPhase 3Delta-Fly Pharma, Inc.NCT03926624Written as Fludarabine
- Optimization of Therapy in Adult Patients With Newly Diagnosed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma by Individualised, Targeted and Intensified TreatmentCompletedPhase 3Goethe UniversityNCT02881086Written as Fludarabine
- Standard Chemoimmunotherapy (FCR/BR) Versus Rituximab + Venetoclax (RVe) Versus Obinutuzumab (GA101) + Venetoclax (GVe) Versus Obinutuzumab + Ibrutinib + Venetoclax (GIVe) in Fit Patients With Previously Untreated Chronic Lymphocytic Leukemia (CLL) Without Del(17p) or TP53 MutationCompletedPhase 3German CLL Study GroupNCT02950051Written as Fludarabine
- Bendamustine Plus Rituximab Versus Fludarabine Plus RituximabCompletedPhase 3University of GiessenNCT01456351Written as Fludarabine 25 mg/m² d 1-3 + Rituximab 375 mg/m² d 1 q4w
- Efficacy/Safety of CPI-613 in Combination With HD Cyt. and Mito. vs HD Cyt. and Mito. in Older Patients With R/R AMLTerminatedPhase 3Cornerstone PharmaceuticalsNCT03504410Written as Fludarabine, Cytarabine, Filgrastim
- Cladribine Combined With G-CSF and Cytarabine as a Salvage Treatment in R/R ALLStatus unknownPhase 2/3The First Affiliated Hospital of Soochow UniversityNCT05578378Written as Fludarabine
- CBA Versus FBA Conditioning Followed by Haploidentical Allogeneic HSCT in Treatment of High Risk and Refractory AMLStatus unknownPhase 3Shanghai General Hospital, Shanghai Jiao Tong University School of MedicineNCT03384225Written as Fludarabine
- CBA Versus FBA Conditioning Followed by Allogeneic HSCT in Treatment of High Risk and Refractory AMLStatus unknownPhase 3Shanghai General Hospital, Shanghai Jiao Tong University School of MedicineNCT03384212Written as Fludarabine
- Randomised Trial in Waldenstrom's MacroglobulinaemiaCompletedPhase 2University College, LondonNCT01592981Written as Fludarabine
- Azacytidine (Vidaza®) Versus Fludarabine and Cytarabine (Fluga Scheme) in Elderly Patients With Newly Diagnosed Acute Myeloid LeukemiaCompletedPhase 3PETHEMA FoundationNCT02319135Written as Fludarabine
- Study Comparing Inotuzumab Ozogamicin In Combination With Rituximab Versus Defined Investigator's Choice In Follicular Non-Hodgkin's Lymphoma (NHL)TerminatedPhase 3PfizerNCT00562965Written as fludarabine
Showing 20 of 24.
What changed recently
From the registry's own updates since Oct 15, 2026.
Started recruiting1
Stopped1
Newly registered2
- Lifileucel (TIL) Therapy After PD-1 Blockade Failure in Kidney CancerNov 9, 2026NCT07925333
- Thiotepa + TBI + Fludarabine + Etoposide for Allo-HSCT in Patients With R/R or High-risk Acute LeukemiaNov 6, 2026NCT07920796
Codes
What other systems call fludarabine · ClinicalTrials.gg INT002787
- MeSH (NLM) C024352fludarabineConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) P2K93U8740FLUDARABINEConfirmed FDA, NLM, Wikidata
- RxNorm 24698Confirmed FDA, Wikidata
- Wikidata Q72478349fludarabineConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C1094FludarabineOne source FDA
- DrugBank DB01073One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C024352 | fludarabine | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | P2K93U8740 | FLUDARABINE | Confirmed FDA, NLM, Wikidata |
| RxNorm | 24698 | — | Confirmed FDA, Wikidata |
| Wikidata | Q72478349 | fludarabine | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C1094 | Fludarabine | One source FDA |
| DrugBank | DB01073 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.